From the Journals

Excellent prognosis for cystic RCC evaluated with radiologic threshold of greater than 50%


 

FROM THE JOURNAL OF UROLOGY

When a standardized radiologic threshold of greater than 50% is used, patients with unifocal cystic renal cell carcinoma (cRCC) have an excellent prognosis with active surveillance and following surgical resection, findings from a new study show.

At a median follow-up of 5.4 years (IQR 2.8-7.8), none of the 138 patients in the cohort experienced a tumor recurrence or metastasis from cRCC, and 7 (5.1%) died from non–renal-related causes. When comparing patients who initially underwent surgery to those who were initially managed with active surveillance, the researchers found that there was no significant difference in overall survival (P = .07). There were no deaths due to kidney cancer in the entire cohort.

The terminology of cRCC has historically been used to describe an indolent version of RCC that consists primarily of cysts, and the threshold of cystic involvement has traditionally been greater than 75% cystic on pathologic examination.

However, this classification does not contribute to the preoperative decision-making process, the study authors noted in Journal of Urology.

Pages

Recommended Reading

FDA approves cabozantinib for the frontline treatment of advanced RCC
MDedge Hematology and Oncology
Mutations linked to checkpoint inhibitor response in RCC
MDedge Hematology and Oncology
In Brazil, few patients get second- and third-line treatment for metastatic RCC
MDedge Hematology and Oncology
Phase 1 study: Human IL-10 plus checkpoint blockade looks promising in RCC, NSCLC
MDedge Hematology and Oncology
OS similar among mRCC patients enrolled in clinical trials across different geographic regions
MDedge Hematology and Oncology
Retroperitoneal lymphadenectomy did not impact OS and DFS for high risk, nonmetastatic renal cell carcinoma
MDedge Hematology and Oncology
Atezolizumab-bevacizumab combo tops sunitinib as first-line therapy for RCC
MDedge Hematology and Oncology
ERV expression may predict response to immune checkpoint blockade in ccRCC, other solid tumors
MDedge Hematology and Oncology
Axitinib/pembrolizumab combo safe, effective against mRCC
MDedge Hematology and Oncology
Immunotherapy regimen influences inflammatory arthritis presentation
MDedge Hematology and Oncology